Gore ME, Szczylik C, Porta C. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.
Article
CAS
PubMed
Google Scholar
Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60:684–90.
Article
PubMed
Google Scholar
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012;13:927–35.
Article
CAS
PubMed
Google Scholar
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.
Article
CAS
PubMed
Google Scholar
Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010;105:1247–54.
Article
PubMed
Google Scholar
Ye DW, Zhang HL. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. OncoTargets Ther. 2014;7:925–35.
Article
CAS
Google Scholar
Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2007;37:755–62.
Article
PubMed
Google Scholar
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084–96.
Article
CAS
PubMed
Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.
Article
CAS
PubMed
Google Scholar
Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health. 2003;57:259–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miyake H, Harada K, Inoue TA, Fujisawa M. Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors. Med Oncol. 2014;31:190.
Article
PubMed
Google Scholar
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–31.
Article
CAS
PubMed
Google Scholar
Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–94.
Article
CAS
PubMed
Google Scholar
Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy. 2012;58:468–74.
Article
CAS
PubMed
Google Scholar
Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016;7:27044–54.
Article
PubMed
PubMed Central
Google Scholar
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, et al. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chin Clin Oncol. 2016;5(1):12.
PubMed
Google Scholar
Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Washington, DC: US Department of Health and Human Services. 2010. http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed 15 Aug 2015.
Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2001;87:881–6.
Google Scholar
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–63.
Article
PubMed
Google Scholar
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.
Article
PubMed
PubMed Central
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115–24.
Article
CAS
PubMed
Google Scholar
Porta C, Szczylik C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, et al. Short and long-term safety with sunitinib in an expanded access trial in matastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(15 Suppl):5114.
Article
CAS
Google Scholar
Van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99:259–65.
Article
PubMed
PubMed Central
Google Scholar
Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377–84.
Article
PubMed
Google Scholar
Herrmann E, Gerss J, Bierer S, Köpke T, Bolenz C, Hertle L, et al. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol. 2009;135:61–7.
Article
CAS
PubMed
Google Scholar
Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer. 2013;108:1571–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010;102:658–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Szczylik C, Cella D, Eisen T, Shah S, Laferriere N, Scheuring U, et al. Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients receiving sorafenib vs interferon-alpha. J Clin Oncol. 2008;26:9603.
Article
CAS
Google Scholar
Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol. 2015;32:78.
Article
PubMed
Google Scholar